Published in PLoS One on February 17, 2011
Prevalence and risk factors for oncogenic human papillomavirus infections in high-risk mid-adult women. Sex Transm Dis (2012) 0.96
Human papillomavirus genotype distribution in Madrid and correlation with cytological data. BMC Infect Dis (2011) 0.85
Short-term natural history of high-risk human papillomavirus infection in mid-adult women sampled monthly. Int J Cancer (2015) 0.83
Persistence, clearance and reinfection regarding six high risk human papillomavirus types in Colombian women: a follow-up study. BMC Infect Dis (2014) 0.79
The DNA load of six high-risk human papillomavirus types and its association with cervical lesions. BMC Cancer (2015) 0.77
Highly Sensitive Detection and Genotyping of HPV by PCR Multiplex and Luminex Technology in a Cohort of Colombian Women with Abnormal Cytology. Open Virol J (2011) 0.77
The cytology and DNA detection by the PapilloCheck(®) test in the diagnosis of human papillomavirus infection. Eur J Microbiol Immunol (Bp) (2013) 0.76
The Prevalence of High-Risk HPV Types and Factors Determining Infection in Female Colombian Adolescents. PLoS One (2016) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol (2003) 16.23
Classification of papillomaviruses. Virology (2004) 14.16
The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol (1995) 10.07
Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol (2003) 7.35
PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol (1997) 5.76
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31
Epidemiology of genital human papillomavirus infection. Am J Med (1997) 4.09
The epidemiology of human papillomavirus infections. J Clin Virol (2005) 3.63
Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis (1999) 3.35
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine (2008) 3.17
Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis (2005) 2.51
Detection and typing of human papillomavirus by e6 nested multiplex PCR. J Clin Microbiol (2004) 2.34
Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer (2002) 2.25
Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol (2004) 2.16
Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol (1996) 2.03
Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis (2001) 1.99
Chapter 12: Human papillomavirus technologies. J Natl Cancer Inst Monogr (2003) 1.67
Environmental co-factors in HPV carcinogenesis. Virus Res (2002) 1.66
Clonal selection for transcriptionally active viral oncogenes during progression to cancer. J Virol (2004) 1.56
Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections. Cancer Epidemiol Biomarkers Prev (2005) 1.53
Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res (2008) 1.40
Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. J Virol Methods (2004) 1.37
Human papillomaviruses and cervical cancer. Adv Cancer Res (1997) 1.32
Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiol Biomarkers Prev (2003) 1.31
HPV and cervical cancer in the 2007 report. Vaccine (2007) 1.23
A novel and rapid PCR-based method for genotyping human papillomaviruses in clinical samples. J Clin Microbiol (2000) 1.23
PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. J Clin Virol (2004) 1.22
The epidemiology of cervical cancer. Cancer J (2003) 1.20
Impact of HPV infection in adolescent populations. J Adolesc Health (2005) 1.19
Risk factors for human papillomavirus exposure and co-factors for cervical cancer in Latin America and the Caribbean. Vaccine (2008) 1.11
Multiple human papilloma virus types in cervical infections: competition or synergy? APMIS (2010) 1.11
Human papillomavirus type 45 propagation, infection, and neutralization. Virology (2003) 1.09
Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med (2007) 1.09
Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region. Vaccine (2008) 1.07
High frequency of multiple HPV types in cervical specimens from Danish women. APMIS (2009) 1.05
Cervical infections by multiple human papillomavirus (HPV) genotypes: Prevalence and impact on the risk of precancerous epithelial lesions. J Med Virol (2009) 1.05
A comparison of early (E7) and late (L1) primer-mediated amplification of papillomaviral DNA in cervical neoplasia. Mol Cell Probes (1996) 1.04
Human papillomavirus type 18 in colorectal cancer. J Microbiol Immunol Infect (2001) 1.01
HLA polymorphisms and cervical human Papillomavirus infection in a cohort of Montreal University students. J Infect Dis (2007) 1.01
Prevalence of single and multiple infection with human papillomaviruses in various grades of cervical neoplasia. J Med Microbiol (1997) 0.99
Genetic susceptibility to infection with human papillomavirus and development of cervical cancer in women in Brazil. Mutat Res (2003) 0.98
Association between HLA-DQB1 alleles and risk for cervical cancer in African-American women. Int J Cancer (1994) 0.96
Regression models for public health surveillance data: a simulation study. Occup Environ Med (2009) 0.95
Single and multiple human papillomavirus infections in cervical abnormalities in Portuguese women. Clin Microbiol Infect (2010) 0.92
Prevalence of human papillomavirus infection in rural villages of the Bolivian Amazon. Rev Inst Med Trop Sao Paulo (2003) 0.91
Frequency of human papillomavirus infection, coinfection, and association with different risk factors in Colombia. Ann Epidemiol (2011) 0.90
Concurrency, sex partner risk, and high-risk human papillomavirus infection among African American, Asian, and Hispanic women. Sex Transm Dis (2010) 0.90
Classical and non-classical HLA molecules and p16(INK4a) expression in precursors lesions and invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol (2008) 0.87
HLA-DQB1 and cervical cancer in Venezuelan women. Gynecol Oncol (2005) 0.83
Human papillomavirus cervical infection in Guarani Indians from the rainforest of Misiones, Argentina. Int J Infect Dis (2004) 0.83
A case-control study of human papillomavirus and cervical squamous intraepithelial lesions (SIL) in Harris County, Texas: differences among racial/ethnic groups. Cad Saude Publica (1998) 0.83
Ethnic differences in risk factors associated with genital human papillomavirus infections. J Adv Nurs (1996) 0.83
Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain. Eur J Public Health (2008) 0.83
Human papillomavirus infection in Honduran women with normal cytology. Cancer Causes Control (2009) 0.79
Life style, environmental and genetic susceptibility to cervical cancer. Toxicology (2004) 0.79
Prevalence of infection with high-risk human papillomavirus in women in Colombia. Clin Microbiol Infect (2008) 0.77
Risk factors for invasive cervical cancer in Latino women. J Med Syst (1996) 0.76
Synthetic genes: a tool for identifying human papillomavirus genotypes by hybridization and polymerase chain reaction-based assays. Diagn Microbiol Infect Dis (2007) 0.76
The translational repressor Pumilio regulates presynaptic morphology and controls postsynaptic accumulation of translation factor eIF-4E. Neuron (2004) 1.79
Liver stage antigen 3 Plasmodium falciparum peptides specifically interacting with HepG2 cells. J Mol Med (Berl) (2004) 1.46
From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet (2010) 1.32
Emotional disclosure through patient narrative may improve pain and well-being: results of a randomized controlled trial in patients with cancer pain. J Pain Symptom Manage (2008) 1.14
Plasmodium vivax: parasitemia determination by real-time quantitative PCR in Aotus monkeys. Exp Parasitol (2002) 1.13
Intimate molecular interactions of P. falciparum merozoite proteins involved in invasion of red blood cells and their implications for vaccine design. Chem Rev (2008) 1.06
Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens. Infect Immun (2002) 1.00
Hepatitis C virus (HCV) E1 and E2 protein regions that specifically bind to HepG2 cells. J Hepatol (2002) 0.95
Immunological profile of a Plasmodium vivax AMA-1 N-terminus peptide-carbon nanotube conjugate in an infected Plasmodium berghei mouse model. Vaccine (2008) 0.94
Plasmodium vivax MSP-1 peptides have high specific binding activity to human reticulocytes. Vaccine (2002) 0.94
Toxoplasma gondii: immunogenicity and protection by P30 peptides in a murine model. Exp Parasitol (2006) 0.92
Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats. J Hypertens (2010) 0.91
Frequency of human papillomavirus infection, coinfection, and association with different risk factors in Colombia. Ann Epidemiol (2011) 0.90
Detection by PCR of human papillomavirus in Colombia: Comparison of GP5+/6+ and MY09/11 primer sets. J Virol Methods (2011) 0.87
Gamma-irradiation effects on biopharmaceutical properties of PLGA microspheres loaded with SPf66 synthetic vaccine. Eur J Pharm Biopharm (2007) 0.86
Expression, polymorphism analysis, reticulocyte binding and serological reactivity of two Plasmodium vivax MSP-1 protein recombinant fragments. Vaccine (2003) 0.86
Structural and immunological principles leading to chemically synthesized, multiantigenic, multistage, minimal subunit-based vaccine development. Chem Rev (2011) 0.85
A highly infective Plasmodium vivax strain adapted to Aotus monkeys: quantitative haematological and molecular determinations useful for P. vivax malaria vaccine development. Vaccine (2003) 0.85
Identifying Plasmodium falciparum merozoite surface protein-10 human erythrocyte specific binding regions. Biochimie (2005) 0.85
The diagnostic performance of classical molecular tests used for detecting human papillomavirus. J Virol Methods (2012) 0.84
Classical molecular tests using urine samples as a potential screening tool for human papillomavirus detection in human immunodeficiency virus-infected women. J Clin Microbiol (2013) 0.84
Plasmodium vivax Duffy binding protein peptides specifically bind to reticulocytes. Peptides (2002) 0.84
Conserved high activity binding peptides are involved in adhesion of two detergent-resistant membrane-associated merozoite proteins to red blood cells during invasion. J Med Chem (2010) 0.84
Structure, Immunogenicity, and Protectivity Relationship for the 1585 Malarial Peptide and Its Substitution Analogues. Angew Chem Int Ed Engl (2001) 0.83
Shortening and modifying the 1513 MSP-1 peptide's alpha-helical region induces protection against malaria. Biochem Biophys Res Commun (2004) 0.82
NMR structure of Plasmodium falciparum malaria peptide correlates with protective immunity. Biochim Biophys Acta (2002) 0.82
Th1 and Th2 immune response to P30 and ROP18 peptides in human toxoplasmosis. Med Microbiol Immunol (2014) 0.81
A comparative study of MHC Class-II HLA-DRbeta1*0401-Col II and HLA-DRbeta1*0101-HA complexes: a theoretical point of view. J Struct Biol (2005) 0.81
Quantum chemical analysis explains hemagglutinin peptide-MHC Class II molecule HLA-DRbeta1*0101 interactions. Biochem Biophys Res Commun (2004) 0.81
Splenectomised and spleen intact Aotus monkeys' immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides. Vaccine (2003) 0.81
Human papillomavirus detection from human immunodeficiency virus-infected Colombian women's paired urine and cervical samples. PLoS One (2013) 0.81
Quantifying Aotus monkey cytokines by real-time quantitative RT-PCR. Cytokine (2004) 0.81
Sequence and expression of MHC-DPB1 molecules of the New World monkey Aotus nancymaae, a primate model for Plasmodium falciparum. Immunogenetics (2002) 0.81
Mtp-40 and alpha antigen gene fragment amplification for the detection of Mycobacterium tuberculosis in Colombian clinical specimens. Mem Inst Oswaldo Cruz (2003) 0.80
Proliferative response of peripheral blood lymphocytes to mitogens in the owl monkey Aotus nancymae. J Med Primatol (2003) 0.80
Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrained. Eur J Immunol (2002) 0.80
Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia. BMC Cancer (2014) 0.80
Mapping the anatomy of a Plasmodium falciparum MSP-1 epitope using pseudopeptide-induced mono- and polyclonal antibodies and CD and NMR conformation analysis. J Struct Biol (2004) 0.79
Distorting malaria peptide backbone structure to enable fitting into MHC class II molecules renders modified peptides immunogenic and protective. J Med Chem (2003) 0.79
Mortality among critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia: a multicenter cohort study in Colombia. Rev Panam Salud Publica (2012) 0.79
Identification of FDA-approved drugs that computationally bind to MDM2. Chem Biol Drug Des (2012) 0.79
Protection against experimental P falciparum malaria is associated with short AMA-1 peptide analogue alpha-helical structures. Biochimie (2002) 0.79
Persistence, clearance and reinfection regarding six high risk human papillomavirus types in Colombian women: a follow-up study. BMC Infect Dis (2014) 0.79
Identification of Plasmodium falciparum reticulocyte binding protein RBP-2 homologue a and b (PfRBP-2-Ha and -Hb) sequences that specifically bind to erythrocytes. Parasitol Int (2004) 0.79
MSP-1 malaria pseudopeptide analogs: biological and immunological significance and three-dimensional structure. Biol Chem (2003) 0.78
Immunogenicity and protectivity of Plasmodium falciparum EBA-175 peptide and its analog is associated with alpha-helical region shortening and displacement. Biol Chem (2003) 0.78
Antibodies induced by Plasmodium falciparum merozoite surface antigen-2-designed pseudopeptides possess neutralizing properties of the in vitro malarial infection. Peptides (2007) 0.78
Detection of lumbosacral nerve root compression with a novel composite nerve conduction measurement. Spine (Phila Pa 1976) (2002) 0.78
Modifying RESA protein peptide 6671 to fit into HLA-DRbeta1* pockets induces protection against malaria. Biochem Biophys Res Commun (2004) 0.77
Analysis of a Plasmodium falciparum EBA-175 peptide with high binding capacity to erythrocytes and their analogues using 1H NMR. J Struct Biol (2003) 0.77
Characterization of a reduced peptide bond analogue of a promiscuous CD4 T cell epitope derived from the Plasmodium falciparum malaria vaccine candidate merozoite surface protein 1. Mol Immunol (2004) 0.77
Conserved regions from Plasmodium falciparum MSP11 specifically interact with host cells and have a potential role during merozoite invasion of red blood cells. J Cell Biochem (2010) 0.77
Induction and displacement of an helix in the 6725 SERA peptide analogue confers protection against P. falciparum malaria. Vaccine (2004) 0.77
Specificity of L1 peptides versus virus-like particles for detection of human papillomavirus-positive cervical lesions in females attending Engativa Hospital, Bogota, Colombia. J Clin Microbiol (2008) 0.77
Plasmodium falciparum SERA protein peptide analogues having short helical regions induce protection against malaria. Biochimie (2003) 0.77
Identification of peptides with high red blood cell and hepatocyte binding activity in the Plasmodium falciparum multi-stage invasion proteins: PfSPATR and MCP-1. Biochimie (2008) 0.77
A pre-PEXEL histidine-rich protein II erythrocyte binding peptide as a new way for anti-malarial vaccine development. Biochem Biophys Res Commun (2007) 0.77
Identifying Plasmodium falciparum EBA-175 homologue sequences that specifically bind to human erythrocytes. Biochem Biophys Res Commun (2004) 0.76
Rv1268c protein peptide inhibiting Mycobacterium tuberculosis H37Rv entry to target cells. Bioorg Med Chem (2013) 0.76
Mycobacterium tuberculosis surface protein Rv0227c contains high activity binding peptides which inhibit cell invasion. Peptides (2012) 0.76
Identification of Plasmodium falciparum RhopH3 protein peptides that specifically bind to erythrocytes and inhibit merozoite invasion. Protein Sci (2008) 0.76
Functional, structural, and immunological compartmentalisation of malaria invasive proteins. Biochem Biophys Res Commun (2007) 0.76
A C-terminal cationic fragment derived from an arginine-rich peptide exhibits in vitro antibacterial and anti-plasmodial activities governed by its secondary structure properties. Peptides (2009) 0.76
Structural characteristics of immunogenic liver-stage antigens derived from P. falciparum malarial proteins. Biochem Biophys Res Commun (2009) 0.76
The Mycobacterium tuberculosis membrane protein Rv0180c: Evaluation of peptide sequences implicated in mycobacterial invasion of two human cell lines. Peptides (2010) 0.76
P. falciparum pro-histoaspartic protease (proHAP) protein peptides bind specifically to erythrocytes and inhibit the invasion process in vitro. Biol Chem (2005) 0.76
Prevalence of HPV-DNA and anti-HPV antibodies in women from Girardot, Colombia. Sex Transm Dis (2009) 0.75
Redefining an epitope of a malaria vaccine candidate, with antibodies against the N-terminal MSA-2 antigen of Plasmodium harboring non-natural peptide bonds. Amino Acids (2013) 0.75
Immunologic evaluation and validation of methods using synthetic peptides derived from Mycobacterium tuberculosis for the diagnosis of tuberculosis infection. Mem Inst Oswaldo Cruz (2013) 0.75
Passive transfer of Plasmodium falciparum MSP-2 pseudopeptide-induced antibodies efficiently controlled parasitemia in Plasmodium berghei-infected mice. Peptides (2008) 0.75
A non-variable L1-peptide displays high sensitivity and specificity for detecting women having human papillomavirus-associated cervical lesions. Peptides (2008) 0.75
Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization. Vaccine (2007) 0.75
Peptides from the Mycobacterium tuberculosis Rv1980c protein involved in human cell infection: insights into new synthetic subunit vaccine candidates. Biol Chem (2010) 0.75